@GENERAPHARM Allow me to add @ASrinivasan into your reply. I am also sharing her presentation in her behalf. She presented at “FY 2021 Generic Drug Science and Research Initiatives Public Workshop”
FDA’s Office of Generic Drugs provided her an opportunity to comment on what they think the Agency should invest in the GDUFA (Generic Drug User fee act). She discussed about the Agency spending on some research related to prevention of formulation nitrosamines in formulation.
FYI. The presentation contains voice over
Watch video here
